The FDA recently approved trastuzumab deruxtecan (T-DXd) in the second line setting. Given the results of DESTINY-Breast03, what is now the role of TDM1 in the treatment armamentarium of HER2+ metastatic breast cancer?
Can trastuzumab emtansine still be effective in sequence after progression on trastuzumab deruxtecan?
Will you be using Trastuzumab deruxtecan (T-DXd) i...
We have no data to support replacing T-DM1 with T-...
Thank you.